1. Home
  2. CBAN vs LUNG Comparison

CBAN vs LUNG Comparison

Compare CBAN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Colony Bankcorp Inc.

CBAN

Colony Bankcorp Inc.

HOLD

Current Price

$20.34

Market Cap

436.6M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.53

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBAN
LUNG
Founded
1975
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
436.6M
57.9M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
CBAN
LUNG
Price
$20.34
$1.53
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
173.4K
393.9K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
2.44%
N/A
EPS Growth
16.91
7.64
EPS
0.39
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
$35.41
$2.48
Revenue Next Year
$4.84
$18.46
P/E Ratio
$51.46
N/A
Revenue Growth
N/A
8.01
52 Week Low
$15.00
$1.13
52 Week High
$21.61
$3.88

Technical Indicators

Market Signals
Indicator
CBAN
LUNG
Relative Strength Index (RSI) 60.18 53.50
Support Level $19.13 $1.36
Resistance Level $21.35 $1.64
Average True Range (ATR) 0.36 0.12
MACD 0.08 0.01
Stochastic Oscillator 77.78 57.78

Price Performance

Historical Comparison
CBAN
LUNG

About CBAN Colony Bankcorp Inc.

Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: